The last recurrence in the long-term study occurred at 5.4 years, leading researchers to be more comfortable using the term ...
Vertex Pharmaceuticals and CRISPR Therapeutics' gene-editing drug is the only sickle cell disease gene therapy on the market for young children.
During its research day, the firm discussed a cell therapy effort in lupus, dubbed "007," and an AI platform for gleaning ...
The firm has raised $78 million to date and is launching its first clinical trial to test a treatment for ...
Despite fears of an innovation slowdown, stoked by funding cuts and FDA personnel shakeups, the agency approved 17 ...
The Phase I/II China-based trial will test the combination in patients with PD-L1-positive, EGFR mutated tumors.
The program will help make genetic counselors available to any provider across different medical specialties in Tennessee and ...
NEW YORK – The European Commission has approved Novartis' gene therapy Itvisma (onasemnogene abeparvovec) for patients at least two years old with 5q-associated spinal muscular atrophy (SMA) and ...
In a Phase III trial, divarasib bested first-generation drugs Lumakras and Krazati, which the firm said could make it a new standard of care in KRAS G12C-mutated NSCLC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results